Cytori Strengthens European Union Sales, Training and Service Operations

San Diego, (PresseBox) - Cytori (NASDAQ:CYTX) has strengthened its Celution System sales, training and service operations through a series of moves to promote the growing commercial activity in Europe.

In September, Cytori opened a sales and training facility in Italy. This facility will allow efficient education of a large number of physicians on the technology, its benefits and the operation of the Celution System. In addition, the facility will support physician training for Cytori's European clinical trial sites, promote direct sales activities and support Cytori's network of European medical distributors.

Three new technical sales representatives will now be based largely in the Italy office. Two are trained physicians responsible for both system sales and the training of physicians and operating room personnel. Each physician has special expertise in breast and cancer surgery. The additional representative is an engineer/dedicated service technician, responsible for device installation, training and service. Each of these individuals will support all EU operations from this facility.

Most recently, Cytori is pleased to announce that it has added a European sales manager to its team. Mr. Marc Thijsselink will coordinate through the main office in Italy to expand commercial efforts in Northern European countries such as Germany, Austria, Switzerland and Eastern Europe. Mr. Thijsselink is a Dutch national and brings to Cytori 20 years of experience in international field sales and 10 years in distribution management. He most recently worked with Allergan as Commercial Business Unit Manager for Emerging Markets. Cytori currently serves the United Kingdom, Scandinavia and France with a dedicated senior sales manager based in London.

"Our dedicated team of six sales and support specialists in Europe is an important asset to Cytori, as evidenced by what they have already accomplished over a short period of time," said Bruce Reuter, senior vice president of international sales, marketing, and distribution for Cytori. "Cytori continues to be able to attract this level of talent due to the potential the Company's technology has to change the way medicine is practiced."

Cautionary Statement Regarding Forward-Looking Statements
This press release includes forward-looking statements regarding events, trends and business prospects, which may affect our future operating results and financial position. Such statements are subject to risks and uncertainties that could cause our actual results and financial position to differ materially. Some of these risks and uncertainties include our history of operating losses, the need for further financing, regulatory uncertainties regarding the collection and results of, clinical data, dependence on third party performance, and other risks and uncertainties described under the "Risk Factors" in Cytori's Securities and Exchange Commission Filings. We assume no responsibility to update or revise any forward-looking statements to reflect events, trends or circumstances after the date they are made.

Cytori Therapeutics, Inc.

Cytori's (NASDAQ:CYTX) goal is to be the global leader in regenerative medicine. The company is dedicated to providing patients with new options for reconstructive surgery, developing treatments for cardiovascular disease, and banking patients' adult stem and regenerative cells. The Celution(R) 800 System is being introduced in Europe into the reconstructive surgery market while the Celution(R) 900 System is being commercialized globally for cryopreserving a patient's own stem and regenerative cells. Clinical trials are ongoing in cardiovascular disease and planned for spinal disc degeneration, gastrointestinal disorders, and other unmet medical needs.

Press releases you might also be interested in

Subscribe for news

The subscribtion service of the PresseBox informs you about press information of a certain topic by your choice at a choosen time. Please enter your email address to receive the email with the press releases.

An error occurred!

Thank you! You will receive a confirmation email within a few minutes.

I want to subscribe to the gratis press mail and have read and accepted the conditions.